v3.26.1
Segment Reporting
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company operates and manages its business as one operating segment, which primarily focuses on developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. The Company's Chief Executive Officer serves as the Company’s Chief Operating Decision Maker, who reviews condensed consolidated financial information on a company-wide basis for purposes of allocating resources and assessing financial performance. The measure of segment assets is reported on the condensed consolidated balance sheets as total assets. The following table represents selected financial information for our segment for the three months ended March 31, 2026 and 2025, in thousands:
Three Months Ended March 31,
20262025
Internal costs
Total salary / benefits$1,896 $5,394 
External costs by program
Zetomipzomib698 6,091 
KZR-261684 
General and administrative3,943 2,430 
Other segment items (1)819 3,030 
Total operating expenses7,365 17,629 
Loss from operations(7,365)(17,629)
Interest income609 1,420 
Gain on sale of nonfinancial asset1,000 — 
Interest expense— (347)
Consolidated segment net loss$(5,756)$(16,556)
(1) Other segment items include stock-based compensation expense, depreciation and amortization and in 2026, a loss on fixed asset write-off.